Polymorphism and Crystalline Forms

Polymorphism is the ability of a drug substance to crystallize in more than one distinct internal arrangement, giving solid forms that share chemical identity but differ in physical properties. Because the crystalline form governs solubility, dissolution rate and physical stability, its identification and control are central preformulation concerns.

Definition

Polymorphism is the occurrence of two or more crystalline forms of the same compound that differ in the arrangement or conformation of molecules in the crystal lattice; related solid-state phenomena include solvates and hydrates (pseudopolymorphs) and the non-crystalline amorphous form.

Scope

The entry covers crystalline polymorphs, solvates and hydrates (pseudopolymorphism), the amorphous state, thermodynamic relationships between forms (enantiotropy and monotropy), the consequences of form for solubility, dissolution and stability, and the principal methods used to detect and characterize forms. It is reference content and not a manufacturing or control specification.

Core questions

• How do different crystalline forms of the same drug differ in solubility, dissolution rate and stability?
• What distinguishes enantiotropic from monotropic polymorphic systems?
• How are polymorphs, solvates and amorphous forms detected and characterized, and why must they be controlled?

Key concepts

• Polymorphs and crystalline forms
• Solvates and hydrates (pseudopolymorphism)
• Amorphous solid state
• Lattice energy and relative stability
• Enantiotropy and monotropy
• Polymorphic transformation
• Powder X-ray diffraction and thermal characterization

Mechanisms

Distinct polymorphs arise when the same molecules pack into different lattices, each with its own lattice energy. A higher-energy (metastable) form has weaker lattice cohesion and therefore greater apparent solubility and faster dissolution, but it tends to convert over time toward the most stable form, which can change product performance. Whether two forms can interconvert reversibly with temperature (enantiotropy) or only irreversibly below the melting point (monotropy) determines processing and storage risk. Solvates and hydrates incorporate solvent into the lattice, again altering solubility and stability, while amorphous solids lack long-range order and offer the highest solubility at the cost of physical instability. Powder X-ray diffraction, thermal analysis and spectroscopy together identify and track these forms.

Clinical relevance

Differences in crystalline form can produce clinically meaningful differences in bioavailability for poorly soluble drugs, and uncontrolled form conversion has historically affected marketed products. This entry describes how solid-state form influences drug behaviour for reference purposes and is not a basis for prescribing or therapeutic decisions.

Evidence & guidelines

Byrn et al. (1995) set out the strategic, regulatory-facing approach to characterizing and controlling pharmaceutical solid forms, an approach reflected in ICH guidance on new drug-substance specifications. The biopharmaceutical consequences of form-dependent solubility connect to the classification framework of Amidon et al. (1995), and the underlying crystallographic principles are treated comprehensively by Bernstein (2002).

History

Awareness that the same drug could exist in different crystalline forms with different performance grew through the second half of the twentieth century, prompting systematic solid-form screening. Byrn et al. (1995) codified a regulatory strategy for pharmaceutical solids, and Bernstein's (2002) monograph consolidated the crystallographic and thermodynamic understanding of polymorphism in molecular crystals.

Key figures

• Stephen R. Byrn
• Joel Bernstein

Seminal works

• byrn-1995
• bernstein-2002

Frequently asked questions

Why does the crystalline form of a drug affect its solubility?

Different polymorphs have different lattice energies; a less stable, higher-energy form requires less energy to break apart and therefore tends to show higher apparent solubility and faster dissolution than the most stable form.

What is the difference between a polymorph and a solvate?

A polymorph is a different crystal packing of the pure drug molecules, whereas a solvate (or hydrate, when the solvent is water) incorporates solvent molecules into the crystal lattice; solvates are sometimes called pseudopolymorphs.